Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial - Summary - MDSpire

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

  • By

  • Rajesh Pahwa

  • Elena Moro

  • Alberto J. Espay

  • Andrew Evans

  • Marie Saint-Hilaire

  • Diego Torres-Russotto

  • Raymond Sanchez

  • Matthew Leoni

  • Sridhar Duvvuri

  • Cari Combs

  • Ih Chang

  • Stacey Tringali

  • Joey Boiser

  • Cindy Zadikoff

  • Angelo Antonini

  • May 1, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy, safety, and tolerability of fixed doses of tavapadon in patients with early Parkinson's disease in a phase 3 trial.

Key Findings:
  • Tavapadon significantly improved motor function compared to placebo, with a p-value < 0.05.
  • The safety profile of tavapadon was acceptable with no new safety concerns identified.
  • Participants receiving tavapadon reported greater improvements in daily living activities, with a PGIC score of 'much improved' in 60% of cases.
Interpretation:

Tavapadon may provide an effective treatment option for early Parkinson's disease, improving motor symptoms while minimizing adverse effects associated with traditional dopaminergic therapies, potentially reshaping treatment strategies.

Limitations:
  • The trial duration was limited to 27 weeks, which may not capture long-term effects.
  • Participants were selected based on specific criteria, which may limit generalizability, and potential biases in selection were not addressed.
Conclusion:

Tavapadon demonstrates potential as a beneficial therapy for early Parkinson's disease, warranting further investigation in longer-term studies, particularly focusing on diverse populations.

Original Source(s)

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

  • by Rajesh Pahwa, Elena Moro, Alberto J. Espay, Andrew Evans, Marie Saint-Hilaire, Diego Torres-Russotto, Raymond Sanchez, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Ih Chang, Stacey Tringali, Joey Boiser, Cindy Zadikoff, Angelo Antonini

  • May 1, 2026

Related Content

AI-driven insights into protein misfolding and innate immunity in neurodegenerative diseases

Advancing rehabilitation in Parkinson’s disease through virtual reality: a narrative review

This Week’s CGT News: Novo’s Parkinson’s Pivot

Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward

  • May 18, 2026

  • 7 min